In a nutshell This study evaluated whether adding carboplatin (Paraplatin) to chemotherapy improved survival for patients with triple-negative breast cancer (TNBC). This study found that this treatment combination improved long-term survival without tumor growth or spread in these patients. Some background TNBC is a type...
Read MoreIn a nutshell This phase 1/2 trial is examining the effectiveness and safety of KY1044 alone and in combination with atezolizumab (Tecentriq) for patients with advanced cancers who are not suitable for any other treatment or have failed all other treatment options. The main outcomes to be measured will be the occurrence and severity of side effects and...
Read More
In a nutshell This study evaluated the impact of radiotherapy on the survival of patients with breast cancer who have undergone surgery. This study found that patients who had radiotherapy after surgery had higher survival than patients who had surgery only. Some background Triple-negative breast cancer (TNBC) is cancer that does not have...
Read More
In a nutshell This study wanted to see how well two medications worked in treating advanced triple negative breast cancer, atezolizumab (Tecentriq) and nab-paclitaxcel (Abraxane). The study found that using these two medications together improved survival in these patients. Some background Triple-negative breast cancer (TNBC) is breast cancer...
Read More
Video information: Breast cancer experts gathered at the 2017 American Society of Clinical Oncology meeting to discuss developments in research and treatment. Patient Power founder, Andrew Schorr, was on-site in Chicago and interviewed Dr. Julie Gralow, Director of Breast Medical Oncology at the Seattle Cancer Care Alliance. Dr. Gralow shares...
Read More
In a nutshell This study investigated the effects of radiotherapy (RT) in older patients with triple-negative breast cancer (TNBC). RT was found to be associated with better survival outcomes for both younger and older patients. Some background TNBC is a form of breast cancer which tests negative for estrogen/ progesterone receptors and human...
Read More
In a nutshell This study examined whether a combination of paclitaxel, capecitabine, and bevacizumab was safe and effective in treating triple-negative, locally-advanced metastatic breast cancer. The three drugs taken together were safe and highly effective in treating these patients. Some background In recent years, many new...
Read More
In a nutshell This paper examined the safety and effectiveness of carboplatin (Paraplatin) and paclitaxel (Taxol) in combination with bevacizumab (Avastin) in triple-negative breast cancer patients. Some background Triple-negative breast cancer describes cancer without the presence of the progesterone receptor, estrogen receptor and human...
Read More
In a nutshell This laboratory based study investigates the use of compounds which block TGF-β signalling in triple negative breast cancer cells. They show that inhibiting this process prevents the development of paclitaxel resistance and the recurrence of cancers following paclitaxel treatment. Some background Triple negative...
Read More
